% | $
Quotes you view appear here for quick access.

Cytokinetics, Incorporated Message Board

  • mofisher22 mofisher22 Jul 7, 2013 2:04 PM Flag

    In comparing CYTK and ACAD one year charts,

    I see a lot of similarity, with ACAD being a few months ahead in their move. I suspect we see a move to the next leg up around $15 very soon, and then make the next base. It has held nicely in the $2.10 pre split, $12.50 post split range, while maintaining high volume. This stock is gaining attention by big money by the day, and momentum should carry it into the mid teens very soon. Anyone have a price prediction leading into the news release at the E uropean conference in a couple months?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't care about charts. Fundamentally, if cardiac trial is a success, FDA will NOT require phase III and will probably give the drug a breakthrough designation, at which point market cap should be about $1.5 bil or $55/share (or $50 assuming they will raise money at $25 or so).
      Additional success in ALS would make it ~3 bil company or ~100-110/share.
      ONYXX is 10 bil on 350 mil in revenue.

    • I guess I would side with redleggi on the 'going into' part of the meeting. Afterwards....a GOOD meeting and mid 20's likely...a GREAT meeting and we're into the 30's and climbing. Our worry will be how soon Amgen makes the move to acquire CYTK as I'm sure they don't want to spend 'milestone' money when they can get more bang for the buck by acquiring it. Don't forget that 'intravenous' is being evaluated at the Sept meeting but 'oral' is the biggest moneymaker of the two. T is an absolute wildcard....

    • $2.50-$3.00...times 6. GLA.

9.27+0.25(+2.77%)Jun 28 4:00 PMEDT